Praxis Precision Medicines (PRAX) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed TG Therapeutics (TGTX) over the past year, gaining 374.5% versus a gain of 58.3%. Over five years, TGTX leads with a +66.2% price change compared with -13.4% for PRAX. TG Therapeutics is the larger company by market cap ($8.48 billion vs $7.26 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | TGTX |
|---|---|---|
| Share price | $259.86 | $55.37 |
| Market cap | $7.26B | $8.48B |
| 1-day change | -1.40% | +3.81% |
| YTD return | -11.83% | +85.74% |
| 1-year return | +374.54% | +58.34% |
| 5-year return | -13.42% | +66.23% |
| P/E ratio (TTM) | — | 19.43 |
| Forward P/E | — | 20.45 |
| EPS (TTM) | $-12.95 | $2.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $616.29M |
| Revenue growth (YoY) | -100.00% | +87.32% |
| Net income (latest FY) | $-303.27M | $447.18M |
| Gross margin | — | 83.66% |
| Operating margin | — | 20.01% |
| Net margin | — | 72.56% |
| 52-week high | $392.70 | $59.30 |
| 52-week low | $50.56 | $26.76 |
| Distance from 52-week high | -33.83% | -6.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +147.99% | +25.90% |
| Average volume | 408.88K | 2.01M |
| Shares outstanding | 27.92M | 153.08M |
| Employees | 168 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed TGTX by 316.2 percentage points over the past year.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs -100.00%).
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
PRAX vs TGTX FAQ
Which is bigger, Praxis Precision Medicines or TG Therapeutics?
TG Therapeutics (TGTX) is larger, with a market capitalization of $8.48B compared with $7.26B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, PRAX or TGTX?
PRAX returned +374.54% over the past 12 months, compared with +58.34% for TGTX (price return, excluding dividends). Past performance does not predict future results.
Are Praxis Precision Medicines and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.